Alpha memo: skeletal muscle resveratrol exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• The opening abstract could more clearly distinguish the cross-context contrast (rodent augmentation vs. human null with possible blunting) rather than front-loading the surprising claim.
• Citing Receipt 2 as 'Olesen et al.-style' is slightly imprecise; the bundle identifies the paper but the author is not confirmed in the memo's author-year prose.

Reviewer note

The memo cleanly executes the Agent-Certified Evidence Map format: one bounded research signal (resveratrol augments training adaptations in rats but fails to translate to skeletal muscle metabolic/inflammatory endpoints in aged men, with a soft negative-interaction signal), two receipts directly supporting that contrast, and explicit caveats about species, dose, duration, and outcome heterogeneity. Title/compound alignment is exact (resveratrol + exercise + skeletal muscle, with cardiac gain noted only as Receipt 1 context). Novelty claims are proportionate — the memo frames Receipt 1 as a prior plausibility-generating finding and Receipt 2 as a direct human test that fails to travel, which is exactly the cross-context contrast the receipts support. Limitations are specific and material (rodent chow dose of 4 g/kg vs. 250 mg/day human; 60–72 y men only; 8 weeks; small per-arm RCT; non-identical endpoints across receipts), and the falsifier is concrete and falsifiable (an adequately powered RCT in older adults at ~250 mg/day ≥8 weeks showing additive effects on PGC-1α, cytochrome c, citrate synthase, and IκB). Source grounding is strong: receipts match bundle entries by title, DOI, year, and excerpt content, and excerpted statistics (PGC-1α ~1.5-fold, cytochrome c ~1.3-fold, COX-I ~1.5-fold, IκB-α/β ~1.3-fold, ~20% carbonylation blunting, ~40% TNFα mRNA blunting) match the Olesen et al. 2014 abstract, while Receipt 1 statistics (21% performance gain, 1.8-fold twitch, 1.2-fold tetanic, 10% LVEF) match the Dolinsky 2012 excerpt. No clinical, policy, or investment claim is made. Accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis